James McCallum, MD
Endocrinology, Diabetes & Metabolism · la Jolla, CANPI 1609838994
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,904 of the $2,388 with a category attached, or 79.7%. 20 manufacturers reported payments, led by Eli Lilly at 28.6% of the total. Reporting peaked in 2024 at $913 and has fallen 53.9% since, to $421 in 2025.
Across 81 payments — averaging $29.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$683
- Insulet Corporation$352
- Dexcom, Inc.$252
- Medtronic$245
- AstraZeneca$166
- Abbott$160
- plus $531 from 14 others
Across 44 payments — averaging $9443.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$254K
- AbbVie$161K
What the payments were for
- Travel & lodging$36715%
- Food & beverage$1,90480%
- Education$1185%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 10 | $683 |
| Insulet Corporation | 17 | $352 |
| Dexcom, Inc. | 15 | $252 |
| Medtronic | 4 | $245 |
| AstraZeneca | 4 | $166 |
| Abbott | 3 | $160 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Tandem Diabetes Care, Inc. | 3 | $88 |
| Antares Pharma, Inc. | 3 | $59 |
| Hologic Sales And Service, LLC | 1 | $48 |
| Novo Nordisk | 2 | $40 |
| Johnson & Johnson | 3 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Lilly USA, LLC | 3 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Merck | 1 | $19 |
| Viiv Healthcare Company | 1 | $18 |
| BETA Bionics, Inc. | 3 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$184
- FARXIGA$125
How this compares
$2,388 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 286 | $384,249 |
| JardianceEmpagliflozin | 179 | $212,752 |
| TrulicityDulaglutide | 131 | $180,671 |
| MounjaroTirzepatide | 81 | $106,039 |
| Teriparatide | 39 | $92,031 |
| ForteoTeriparatide | 20 | $80,343 |
| JanuviaSitagliptin Phosphate | 55 | $76,054 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $54,533 |
| FarxigaDapagliflozin Propanediol | 35 | $44,546 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 42 | $44,007 |
| GenotropinSomatropin | 18 | $37,513 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $32,938 |
| RybelsusSemaglutide | 15 | $32,612 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $32,544 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $29,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $40 | $440,638340 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Lyumjev, Humalog | $27 | $407,474307 claims |
| MerckJanuvia | $19 | $76,05455 claims |
| AstraZenecaFarxiga | $166 | $44,54635 claims |
| Johnson & JohnsonInvokana | $36 | $27,84316 claims |
| Sanofi-aventis U.S. LLCLantus | $90 | $6,20947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in la Jolla
- Daniel Einhornla Jolla$578K
- Athena Philis-Tsimikasla Jolla$574K
- Matthew Levinela Jolla$134K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.